Extraction of a substance with calcitonin-like immunoreactivity from pituitary glands of intact and thyroidectomized rats

A high-fat diet increases calcitonin secretion in the rat

We have studied the effects of diet-induced obesity on thyroidal calcitonin, plasma calcitonin, calcium and phosphorus in rats. Twelve 9-week-old female rats were randomly divided into two groups. One group was fed a low-fat diet while the other was fed a high-fat diet. Both diets had 0.76% Ca, 0.56% P and 2.2 U/g vitamin D; however, the high-fat diet had hydrogenated vegetable oil added at 405 g/kg. All rats were pair-fed and consumed 11 g/day per rat for 27 weeks at which time the rats were fasted overnight and exsanguinated. The rats on the high-fat diet weighted 406 +/- 21 g (mean +/- SEM) versus 292 +/- 13 g for controls and had higher levels of serum calcitonin (104 +/- 12 versus 57 +/- 9 pg/ml). The obese rats also had increased thyroidal calcitonin by radioimmunoassay and increased thyroidal C-cells by immunohistology. The increased calcitonin levels occurred without a concomitant increase in calcium levels. These data indicate that a high-fat diet in rats stimulates C-cell growth and calcitonin secretion.

Pituitary cells secrete calcitonin in the reverse hemolytic plaque assay

Rat pituitary cells were evaluated in the reverse hemolytic plaque assay for calcitonin (CT) secretion. The secretion of CT could be demonstrated by the formation of hemolytic plaques around single pituitary cells when a specific CT antibody was used. Approximately 0.1 percent of the cells secreted CT in the basal state. Phorbol stimulated CT secretion by up to 25-fold. The diameter of the hemolytic plaques around pituitary cells from genetically obese (Zucker) rats was significantly greater than normal rats (24 versus 37 microns). This study demonstrates that pituitary cells secrete CT and that the secretion may be regulated by pharmacological agents (phorbol) and physiological signals (obesity).

Immunoreactive calcitonin in brain regions and pituitary of sheep

In this study we have investigated the presence of immunoreactive calcitonin in the central nervous system and pituitary of sheep. The calcitonin concentrations were determined radioimmunologically by two different antibodies. We have demonstrated calcitonin in extracts of areas of the central nervous system, whole pituitary, thyroid gland and plasma of 21 sheep. The concentrations were (ng/g wet weight, mean values +/- SE): thyroid 16.0 +/- 4.4, pituitary 2.03 +/- 0.34, reticular formation 1.64 +/- 0.25, substantia nigra 1.53 +/- 0.46, dentate nucleus 1.11 +/- 0.27, putamen 1.05 +/- 0.35, hippocampus 0.97 +/- 0.17, fornix 0.96 +/- 0.15, anterior thalamus 0.92 +/- 0.28, mammillary body 0.88 +/- 0.12, cerebellum 0.86 +/- 0.09, caudate nucleus 0.84 +/- 0.11, posterior hypothalamus 0.83 +/- 0.19, epiphysis 0.75 +/- 0.25, thalamus centralis 0.71 +/- 0.10, almond nucleus 0.69 +/- 0.16, medulla oblongata 0.67 +/- 0.15, anterior hypothalamus 0.66 +/- 0.20, precentral gyrus 0.66 +/- 0.16, globus pallidus 0.63 +/- 0.31, postcentral gyrus 0.36 +/- 0.08 and plasma (ng/ml) 0.058 +/- 0.013. Our results demonstrate that immunoreactive calcitonin is present in the central nervous system (CNS) of sheep, compatible with a neurotransmitter function for this hormone.

Novel peptides from the calcitonin gene: expression, receptors and biological function

Calcitonin gene products include calcitonin and its carboxyl-terminal flanking peptide (in man PDN-21), and calcitonin gene-related peptide (CGRP). Alternative splicing of the initial gene transcripts results in the production of two distinct messenger RNA encoding precursors of CGRP and of calcitonin. CGRP messenger RNA is the predominant transcription product of the calcitonin gene in neural tissues, but it is also present in the pituitary and the C-cells of normal thyroid glands and in medullary thyroid carcinoma. Immunoreactive CGRP has, moreover, been recognized around blood vessels of the heart. Calcitonin and PDN-21 are cosecreted from thyroid C-cells, but they are also found in the brain and pituitary. CGRP receptors are present in the brain and the heart, and calcitonin receptors in bone and kidney cells and in the hypothalamus. Calcitonin administered peripherally and in vitro inhibits bone resorption and stimulates renal 1.25-dihydroxycholecalciferol production. CGRP used in the same manner has potent cardiovascular effects (vasodilation, hypotension, positive chronotropic and inotropic action in the heart). Intracerebroventricular administration of CGRP raises the blood pressure, and both CGRP and calcitonin inhibit gastric acid secretion and food intake. The distinct but overlapping effects of calcitonin and CGRP raise important regulatory and functional issues.